Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion

Source :: PR Newswire. August 8, 2024
Publication Year :: 2024
Abstract: Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in [...]

Subjects :: Boehringer Ingelheim GmbH -- Company sales and earnings
Eli Lilly and Co. -- Company sales and earnings
Pharmaceutical industry -- Company sales and earnings
Insulin lispro
Company earnings/profit
Business
News, opinion and commentary
Jardiance (Medication)
Trulicity (Medication)
Verzenio (Medication)
Baqsimi (Medication)
Mounjaro (Medication)
Zepbound (Medication)

Tools